Are we to take you seriously when you posted this?
What did Barron's article say about GERN ?
by bokka_raton • 7 hours ago
Can anyone post the details ?
Did you ever consider that "Chippy" didn't want the share price to soar until he got his options locked in? Would you do the same? Of course you would! Let is rest man, we ALL heard ya.
mlbox, I wouldn't overlook MEIP as a trading stock. It is priced below cash and will certainly run up at least 50% in six months.
Schubert Jonckheer & Kolbe LLP launched an investigation today into the conduct of retail pharmacies CVS and Rite Aid
Schubert Jonckheer & Kolbe LLP has launched an investigation into whether certain officers and directors of MiMedx Group, Inc. (NASDAQ: MDXG) breached their fiduciary duties to MiMedx and its shareholders.
Schubert Jonckheer & Kolbe LLP has launched an investigation into whether certain officers and directors of St. Jude Medical, Inc. STJ, +0.58% breached their fiduciary duties to St. Jude and its shareholders.
Schubert Jonckheer & Kolbe LLP is investigating potential claims on behalf of purchasers of the securities of Zynga, Inc. ("Zynga" or the "Company") (Nasdaq: ZNGA), concerning potential violations of federal securities laws and breaches of fiduciary duty by certain insiders, including Zynga’s CEO, Mark Pincu
The list goes on and on......
Late-stage products expected to drive growth in the next several years, following regulatory approvals, include daratumumab for multiple myeloma; sirukumab for rheumatoid arthritis; guselkumab for psoriasis; JNJ-927 (ARN-509) for pre-metastatic prostate cancer; imetelstat for myelofibrosis; JNJ-493 (FGFRi kinase inhibitor) for urothelial cancer; esketamine for treatment-resistant depression; AL-8176 for respiratory syncytial virus (RSV); fulranumab for osteoarthritic pain; JNJ-872 (VX-787) for influenza A; JNJ-922 (Orexin-2 antagonist) for primary insomnia; and AL-335 for hepatitis C.4 In addition, daratumumab and esketamine have both received Breakthrough Therapy Designations from the U.S. Food and Drug Administration (FDA). Janssen is also announcing today that it plans to submit a Biologic Licensing Application to the FDA and a Marketing Authorization Application to the EMA this year for daratumumab in double refractory multiple myeloma. The submission will be based on Phase 2 data, which will be presented at the upcoming American Society of Clinical Oncology (ASCO) meeting.